BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15899725)

  • 61. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function.
    Hohage H; Zeh M; Heck M; Gerhardt UW; Welling U; Suwelack BM
    Transplant Proc; 2005 May; 37(4):1748-50. PubMed ID: 15919453
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.
    MacDonald AS
    Transplant Proc; 2003 May; 35(3 Suppl):201S-208S. PubMed ID: 12742497
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.
    Kahan BD; Wong RL; Carter C; Katz SH; Von Fellenberg J; Van Buren CT; Appel-Dingemanse S
    Transplantation; 1999 Oct; 68(8):1100-6. PubMed ID: 10551636
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Proteinuria following a switch from calcineurin inhibitors to sirolimus.
    Letavernier E; Pe'raldi MN; Pariente A; Morelon E; Legendre C
    Transplantation; 2005 Nov; 80(9):1198-203. PubMed ID: 16314786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation.
    Vilalta R; Vila A; Nieto J; Callís L
    Transplant Proc; 2003 Mar; 35(2):703-4. PubMed ID: 12644102
    [No Abstract]   [Full Text] [Related]  

  • 66. Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients.
    Mansell H; Shoker A; Alcorn J; Fenton ME; Tam JS; Semchuk W; Bashir B; Kraft WK; Yao S; Douketis JD
    Clin Transl Sci; 2022 Jul; 15(7):1687-1697. PubMed ID: 35439353
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
    Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
    N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sirolimus pharmacokinetic differences between children and adults.
    Venkataramanan R; Sindhi R
    Pediatr Transplant; 2006 Dec; 10(8):872-4. PubMed ID: 17096752
    [No Abstract]   [Full Text] [Related]  

  • 70. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.
    Renders L; Czock D; Schöcklmann H; Kunzendorf U
    Int J Clin Pharmacol Ther; 2003 Nov; 41(11):499-503. PubMed ID: 14620947
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient.
    Shinke H; Hashi S; Kinoshita R; Taniguchi R; Sugimoto M; Matsubara K; Ogawa E; Sonoda M; Takada N; Yoshizawa A; Ogawa K; Okamoto S; Uemoto S; Masuda S
    Biol Pharm Bull; 2013; 36(7):1221-5. PubMed ID: 23676788
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interaction of chloramphenicol and the calcineurin inhibitors in renal transplant recipients.
    Mathis AS; Shah N; Knipp GT; Friedman GS
    Transpl Infect Dis; 2002 Sep; 4(3):169-74. PubMed ID: 12421465
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
    Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
    Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?
    Vanrenterghem YF
    Curr Opin Nephrol Hypertens; 1999 Nov; 8(6):669-74. PubMed ID: 10630811
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.